200 related articles for article (PubMed ID: 31028744)
1. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
[TBL] [Abstract][Full Text] [Related]
2. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
Esposito MT; Zhao L; Fung TK; Rane JK; Wilson A; Martin N; Gil J; Leung AY; Ashworth A; So CW
Nat Med; 2015 Dec; 21(12):1481-90. PubMed ID: 26594843
[TBL] [Abstract][Full Text] [Related]
4. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C; Portwood SM; Przespolewski A; Wang ES
Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
6.
Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
[No Abstract] [Full Text] [Related]
7. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Csizmar CM; Saliba AN; Swisher EM; Kaufmann SH
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945003
[TBL] [Abstract][Full Text] [Related]
9. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
[TBL] [Abstract][Full Text] [Related]
10. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors in acute myeloid leukaemia therapy: How a synthetic lethality approach can be a valid therapeutic alternative.
Gafencu GA; Tomuleasa CI; Ghiaur G
Med Hypotheses; 2017 Jul; 104():30-34. PubMed ID: 28673584
[TBL] [Abstract][Full Text] [Related]
13. Unifying targeted therapy for leukemia in the era of PARP inhibition.
Boila LD; Sengupta A
Exp Hematol; 2023 Aug; 124():1-14. PubMed ID: 37236341
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA repair pathways in AML.
D'Andrea AD
Best Pract Res Clin Haematol; 2010 Dec; 23(4):469-73. PubMed ID: 21130409
[TBL] [Abstract][Full Text] [Related]
15. PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment.
Zhao L; So CW
Exp Hematol; 2016 Oct; 44(10):902-7. PubMed ID: 27473567
[TBL] [Abstract][Full Text] [Related]
16. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
[TBL] [Abstract][Full Text] [Related]
17. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
18. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
19. High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
[TBL] [Abstract][Full Text] [Related]
20. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation.
Lu AZ; Abo R; Ren Y; Gui B; Mo JR; Blackwell D; Wigle T; Keilhack H; Niepel M
Biochem Pharmacol; 2019 Sep; 167():97-106. PubMed ID: 31075269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
